Vertex Pharmaceuticals Incorporated
Market Cap
$118.31B
P/E Ratio
30.44
EPS
$15.30
Dividend Yield
0.00%
52-Week Range
$362.50 — $517.20
Volume
573.94K
Avg Volume
1.47M
Beta
0.32
P/E (TTM)
30.44
Forward P/E
24.11
PEG Ratio
3.69
P/S (TTM)
9.64
P/B (TTM)
6.21
P/FCF
87.84
EV/EBITDA
71.53x
EV/Sales
—
ROE (TTM)
0.23%
ROA (TTM)
0.15%
ROIC
0.06%
Gross Margin
0.86%
Operating Margin
0.35%
Net Margin
0.35%
Debt/Equity
0.21
Current Ratio
2.90
EPS Growth (YoY)
+0.05%
Revenue Growth (YoY)
+0.12%
EPS Growth (3Y)
+2.46%
EPS Growth (5Y)
+1.53%
Sales Growth (3Y)
+0.10%
Sales Growth (5Y)
+0.14%
EPS Est (This Year)
$19.32
EPS Est (Next Year)
$22.16
Dividend Yield
—
Annual Dividend
—
Payout Ratio
0.00%
Frequency
—
Ex-Dividend Date
—
Cash/Share
$26.04
Buy
1 = Strong Buy, 5 = Strong Sell
Price Target Range
Consensus Target: $549.31(17.9% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
254.00M
Float
253.20M
Free Float %
99.68%
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
NASDAQ
IPO Date
1991-07-24
Employees
6100
CEO
Reshma Kewalramani
Index Membership
S&P 500
Website
https://www.vrtx.com
Vertex Pharmaceuticals Incorporated (VRTX) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $118.31B, a P/E ratio of 30.44, VRTX is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare VRTX against other stocks using dozens of fundamental and technical filters.
Vertex Pharmaceuticals Incorporated (VRTX) has a trailing twelve-month (TTM) P/E ratio of 30.44. This is above the market average, which may reflect high growth expectations or premium valuation. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Vertex Pharmaceuticals Incorporated (VRTX) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Vertex Pharmaceuticals Incorporated (VRTX) has a market capitalization of $118.31 billion, classifying it as a large-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Buy" rating on Vertex Pharmaceuticals Incorporated (VRTX) with an average score of 2.00 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $549.31 implies 17.9% upside from the current price.